The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at helping individuals lose weight. However, a new population-wide study being presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Vienna (15-19 Sept) finds that half of adults without diabetes who start taking the weight-loss drug semaglutide in Denmark discontinue treatment within a year.
“This level of drop off is…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply